Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: Influence of pre-existing anti-vector immunity

Journal of General Virology

Volumn 82, Issue 9, 2001, Pages 2215-2223

  Sharpe, S ^a   Polyanskaya, N ^a   Dennis, M ^a   Sutter, G ^a   Hanke, T ^a   Erfle, V ^a   Hirsch, V ^a   Cranage, M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VACCINIA VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GENE CONSTRUCT; GENE EXPRESSION; IMMUNE RESPONSE; LYMPH NODE; LYMPHOCYTE ACTIVATION; LYMPHOID TISSUE; MACACA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSGENE; VACCINATION; VACCINIA VIRUS; VIRUS ATTENUATION; VIRUS IMMUNITY;

EID: 0034857126     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-82-9-2215     Document Type: Article

References (39)

1. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus
2. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing HIV 89.6 envelope protein
3. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by pre-existing poxvirus immunity
4. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells
5. mac251: Dependence on route of challenge exposure
6. Compact, synthetic, vaccinia virus early/late promoter for protein expression
7. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein
8. Immune responses to both cellular and viral proteins can mediate protection against infection with SIVmac
9. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques
10. Anti-HIV cellular immunity: Recent advances towards vaccine design
11. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
12. Patterns of virus replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia Ankara
13. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
14. Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxvirus
15. A high frequency of Mamu-A*01 in the rhesus macaque detected by PCR-SSP and direct sequencing
16. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques
17. Progress in the development of an HIV-1 vaccine
18. A new look at T cells
19. Abstammung Eigenschaften und Verwendug des attenuierten Vaccinia-Stammes MVA
20. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
21. Definition of an epitope and MHC class I molecule recognized Gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys
22. Mechanism of genital transmission of SIV: A hypothesis based on transmission studies and the location of SIV in the genital tract of chronically infected female rhesus macaques
23. Vaccinia virus: A tool for research and vaccine development
24. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) gag-pol and/or env in macaques challenged with pathogenic SIV
25. Applications of poxvirus vectors to vaccination: An update
26. Mucosal exposure to subinfectious doses of SIV primes gut-associated antibody secreting cells and T cells: Lack of enhancement by nonneutralizing antibody
27. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector
28. Immunisation with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: Long-term protection and vaccine effect of vaccination
29. Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants
30. Live attenuated AIDS viruses as vaccines: Promise or peril?
31. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag-pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
32. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) gag-pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
33. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques
34. Non-replicating vaccinia vector efficiently expresses recombinant genes
35. Non-replicating vaccinia vector efficiently expresses bacteriophage T7 R polymerase
36. Rapid screening for Mamu A*01 positive rhesus macaques using a SIVmac Gag peptide-specific cytotoxic T-lymphocyte assay
37. Presence of circulating CTL induced by infection with wild-type or attenuated SIV and their correlation with protection from pathogenic SHIV challenge
38. Human Immunodeficiency virus type 1 envelope glycoprotein-specific cytotoxic T lymphocytes in simian-human immunodeficiency virus-infected rhesus monkeys
39. Protection from rabies by a vaccinia virus containing the rabies virus glycoprotein gene